Development and validation of a novel model based on hematological biomarkers for predicting risk factors and outcomes in cancer patients with carbapenem-resistant organism infection
Frontiers in Public Health · 08.04.2026 · 14
DOI: 10.3389/fpubh.2026.1734259 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Frontiers in Public Health, online erschienen am 08.04.2026. Verfasst von Bin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Carbapenems, Bacterial Infections. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study aimed to develop and validate a novel model for predicting mortality risk in cancer patients with carbapenem-resistant organism (CRO) infections.
Methods
Cancer patients with CRO infections in Henan Cancer Hospital between January 2022 and March 2024 were included in this retrospective study. LASSO regression was used to construct a novel model for predicting mortality in cancer patients with CRO infections. Receiver operating characteristic (ROC), decision curve analysis (DCA), and clinical impact curves (CIC) were used to assess the predictive ability and clinical utility of the prediction model.
Results
A total of 417 cancer patients with CRO infections were included in the study. Fourteen factors were selected, including sample source, radiotherapy, blood culture, exposure to antibiotics after susceptibility testing, lymphocyte-to-monocyte ratio (LMR), lymphocyte-to-monocyte ratio (LMR), total protein (TP), blood urea nitrogen (BUN), calcium (CA), C-reactive protein (CRP), triglyceride (TG), procalcitonin (PCT), prothrombin time (PT), and thrombin time (TT), which were found to be associated with 30-day mortality in cancer patients with CRO infections. The areas under the ROC curve for the prediction model were 0.815 (95% CI: 0.767–0.857) and 0.801 (95% CI: 0.716–0.871) for the primary cohort and validation cohort, respectively. The models demonstrated good predictive accuracy, with p -values 0.479 and 0.786 on the Hosmer–Lemeshow test. DCA and CIC analyses confirmed the clinical utility of the prediction model.
Conclusion
Our model could be used as an effective individualized risk prediction tool for clinicians. It would provide personalized risk assessments for cancer patients with CRO infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Central Sterilization Supply Department, The Guanghua Stomatological College of Sun Yat-sen University, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China.
- Department of Clinical Laboratory, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zitieren
APA
Li, B., Wen, X., Jing, M., Qu, Y., Zhang, J., Xu, Q., Chen, S., & Xue, N. (2026). Development and validation of a novel model based on hematological biomarkers for predicting risk factors and outcomes in cancer patients with carbapenem-resistant organism infection. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1734259
Vancouver
Li B, Wen X, Jing M, Qu Y, Zhang J, Xu Q, et al. Development and validation of a novel model based on hematological biomarkers for predicting risk factors and outcomes in cancer patients with carbapenem-resistant organism infection. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1734259
BibTeX
@article{Li2026,
author = {Li, Bin and Wen, Xiaoyan and Jing, Min and Qu, Yuanye and Zhang, Junhua and Xu, Qingxia and Chen, Shulin and Xue, Ning},
title = {Development and validation of a novel model based on hematological biomarkers for predicting risk factors and outcomes in cancer patients with carbapenem-resistant organism infection},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1734259}
}
EUVIMED